Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HFSRT with Nivolumab, Ipilimumab, and Bevacizumab in Recurrent High Grade Gliomas
NCT02829931Phase 1Completed
- Sponsor
- Moffitt Cancer Center
- Start
- Aug 2016
- Primary completion
- Aug 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of nivolumab, ipilimumab and bevacizumab in malignant glioma, sponsored by Moffitt Cancer Center. Started Aug 2016; status: completed.
02
Drugs
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT02829931.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02829931.